Acelyrin bags $300 million Series C for Phase III izokibep development

Acelyrin, a late-stage clinical biopharma company focused on accelerating the delivery of transformative medicines in immunology, has announced a $300 million Series C financing to fund izokibep Phase III development in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA).

The Series C financing was led by Access Biotechnology (Kosdaq: A950130) with participation from Acelyrin's existing investors AyurMaya. Others involved included an affiliated fund of Matrix Capital Management, Westlake Village BioPartners, Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, Samsara BioCapital, Surveyor Capital, Tybourne Capital Management, and venBio Partners.

Since the beginning of 2022, the USA-based company has secured a record $550 million in private equity financing, which has been used to fund the development of izokibep in hidradenitis suppurativa and uveitis, explore several potential new indications, and continue to aggressively pursue portfolio expansion through high-value business development opportunities.